| ObjectiveExplore the17-βE2-joint cisplatin for ovarian cancer cell growth and HO 8910-in effect of apoptosis mechanismsMethods1 Methyl thiazolyl tetrazolium(MTT) method method detection of different concentrations of estrogen cisplatin combination in application of cell proliferation.2 Flow cytometric analysis of different concentrations of cisplatin combination in estrogen application in cell apoptosis.Results1.Inverted microscope HO-8910 human ovarian cancer cell morphology(1)Control group:Ovarian cancer cells in good condition, cell stretch, cobblestone-like, over time, cells gradually increased and cell contacts close.(2) 17-βE2cisplatin in ovarian cancer cell group under the same time:24h when the ovarian cancer can still form, a small amount of cytoplasm, vacuoles, cell gap between cells began to appear; 72h, the shrinkage is not clear dead cells, significantly smaller volume of space increases, some cells can be seen fragments of the nucleus, while the cytoplasm remained intact.(3)17-βE2alone ovarian cancer and cisplatin after 24h after the interaction group:24h in good condition when the ovarian cancer cell growth;48h after the cell shape, small cytoplasmic vacuoles, intercellular start getting larger, part of the fragmentation of the nucleus can be seen dead cells.(4) Ovarian cancer with cisplatin alone a joint 17-βE2 48h joint action group:24h when no significant cell space and shrinkage.72h, the medium can be seen with a large number of drug deaths of cell suspension, a small number of dead cells without signs of nuclear fragmentation, cell shrinkage significantly.2.17-βE2 combined with cisplatin on human ovarian cancer cell line HO-8910 inhibited the proliferation effect(1) 17-(3E2 cisplatin in ovarian cancer cell group under the same time:the detection time significantly inhibited the proliferation of ovarian cancer, compared with the control group significantly (p<0.05). Concentration of estrogen liquid 1×10-7mol/l 72h when the interaction of cisplatin on ovarian cancer inhibition was most significant value-added, the two drugs have synergistic effects (q>1.15).(2) 17-βE2 alone after 24h after ovarian cancer and cisplatin interaction group:24h light to ovarian cancer cells to promote proliferation, but the difference was not statistically significant (p> 0.05);48h,72h ovarian cancer when Cell proliferation was increased to varying degrees (p<0.05) were statistically significant.Concentration of estrogen liquid 1×10-6mol/l,1×10-7mol/l, the two drugs have synergistic effects (q>1.15).Concentration of 1×10-7mol/l of estrogen interaction with cisplatin 72h inhibitory effect on ovarian cancer the most significant value.(3) Ovarian cancer with cisplatin alone a joint 17-PE248h joint action group:24h,48h ovarian carcinoma cell lines when more stable, compared with control group (p<0.05) was statistically significant; 72h when the ovarian cancer cell proliferation in experimental group significantly increased (p<0.05) were statistically significant. Cisplatin alone by the joint concentration of 1×10-7 mol/l common effect of estrogen on ovarian cancer cells to 72h, value-added impact of the most significant inhibition of the two drugs have a synergistic effect (q> 1.15).3.Flow cytometric detection 17-β3E2 cisplatin combination of ovarian cancer cell apoptosis HO-8910(1) 17-βE2 cisplatin in ovarian cancer cell group under the same time:72h when the concentration of drugs for ovarian cancer cell apoptosis rates were 17.86%,22.22%,14.85%, 3.94% and 3.66% compared to the control group, the difference was statistically (p<0.05).(2) 17-βE2 alone after 24h after ovarian cancer and cisplatin interaction group:72h when the concentration of drugs for ovarian cancer cell apoptosis rates were 10.85%, 11;97%,7.21%,3.91% and control group relatively higher than 3.75%, the difference was statistically significant (p<0.05).(3)Ovarian cancer with cisplatin alone a joint 17-βE248h joint action group:72h when the concentrations of drugs from the ovarian cancer cell lines were 23.48%,26.88%, 23.94%,17.85% 3.13% compared with the control group, the difference was statistically significant (p<0.05).Conclusion: 1.Short simple application 17-(3E? little effect on cell growth, suggesting that ovarian cancer patients before and given a short period of hormone replacement therapy does not cause disease progression.2.Cisplatin in combination with the 17-βE2 inhibit ovarian cancer cell proliferation and apoptosis in ovarian cancer cells.Clinical applications can enhance the sensitivity to cisplatin, increased chemotherapy.3.17-βE2 cisplatin effect on people after the cells, and ovarian cancer cell proliferation, promote cell apoptosis than cisplatin, with 17-βE2 combined application effect is better. Clinical application,give patients after treatment, cisplatin chemotherapy, the effect of hormone, both should be better.4.Ovarian cancer surgery or treatments after hormone replacement therapy can improve patients'mental state, and improve the quality of life, make humanized treatment meet the new standards. |
PDF Full Text Request